Prodrugs in cancer chemotherapy

At present, chemotherapy is not very effective against common solid cancers especially once they have metastasised. However, laboratory experiments and studies on dose intensification in humans have indicated that some anti-cancer agents might be curative but only if the dose given was very much higher than that presently obtainable clinically. Prodrugs, activated by enzymes expressed at raised level in tumors, can deliver at least 50-fold the normal dose and can cure animals with tumors normally resistant to chemotherapy. This approach has not yet proved to be practicable clinically because of the rarity of human tumors expressing a high level of an activating enzyme. However, new therapies have been proposed overcome this limitation of prodrug therapy. Enzymes that activate prodrugs can be directed to human tumor xenografts by conjugating them to tumor associated antibodies. After allowing for the conjugate to clear from the blood a prodrug is administered which is normally inert but which is activated by the enzyme delivered to the tumor. This procedure is referred to as ADEPT (antibody-directed enzyme prodrug therapy). Early clinical trials are promising and indicate that ADEPT may become an effective treatment for all solid cancers for which tumor associated or tumor specific antibodies are known. Tumors have also been targeted with the genes encoding for a prodrug activating enzymes. This approach has been called genedirected enzyme prodrug therapy (GDEPT) or VDEPT (virus-directed enzyme prodrug therapy) and has shown good results in animal models. These new therapies may finally realise the potential of prodrugs in cancer chemotherapy.

[1]  A. Harris,et al.  Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. , 1995, British Journal of Cancer.

[2]  R. Tompkins,et al.  Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. , 1992, Cancer research.

[3]  W. Whitmore,et al.  Therapeutic trial of aniline mustard in patients with advanced cancer. Comparison of therapeutic response with cytochemical assessment of tumor cell β‐glucuronidase activity , 1976 .

[4]  T. Curiel,et al.  Editorial: Cancer Research: Does It Deliver for the Patient? Phase I Study of Interleukin-2 Combined with Interferon-a and 5-fluorouracil in Patients with Metastatic Renal Cell Cancer. Effect of Liposome-muramyl Tripeptide Combined with Recombinant Canine Granulocyte Colony-stimulating Factor on Can , 2022 .

[5]  C. Springer,et al.  A cytotoxic agent can be generated selectively at cancer sites. , 1988, British Journal of Cancer.

[6]  L. Davies,et al.  Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). , 1995, Biochemical pharmacology.

[7]  K. D. Bagshawe,et al.  Antibody directed enzymes revive anti-cancer prodrugs concept. , 1987, British Journal of Cancer.

[8]  C. Springer,et al.  Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. , 1996, Cancer research.

[9]  I. Maxwell,et al.  Expression of the diphtheria toxin A-chain coding sequence under the control of promoters and enhancers from immunoglobulin genes as a means of directing toxicity to B-lymphoid cells. , 1991, Cancer research.

[10]  P. Burke,et al.  Synthesis of an aminopropyl analog of the experimental anticancer drug tallimustine, and activation of its 4-nitrobenzylcarbamoyl prodrug by nitroreductase and NADH , 1997 .

[11]  D. Waxman,et al.  Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. , 1995, Cancer research.

[12]  F. Friedlos,et al.  A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. , 1988, Biochemical pharmacology.

[13]  I. Kawase,et al.  Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. , 1994, Cancer research.

[14]  R. Vile,et al.  Targeted vectors for gene therapy , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  H. Dvorak,et al.  Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. , 1994, Cancer research.

[16]  F. Friedlos,et al.  Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. , 1991, Biochemical pharmacology.

[17]  X. Breakefield,et al.  Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  F. Friedlos,et al.  The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). , 1992, Biochemical pharmacology.

[19]  R. Vile,et al.  Targeted gene therapy. , 1995, British medical bulletin.

[20]  E. Borrelli,et al.  Targeting of an inducible toxic phenotype in animal cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Roberts,et al.  The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) , 1991, Biochemical pharmacology.

[22]  P. Wen,et al.  Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo , 1996, Nature Medicine.

[23]  P. Musiani,et al.  5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. , 1995, Journal of immunology.

[24]  D. Waxman,et al.  Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. , 1996, Cancer research.

[25]  H. P. Fell,et al.  Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. , 1993, Cancer research.

[26]  P. Wen,et al.  Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. , 1996, Gene therapy.

[27]  J. Bertino,et al.  Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2. , 1989, Cancer research.

[28]  T. A. Connors,et al.  Cure of Mice bearing Advanced Plasma Cell Tumours with Aniline Mustard : the Relationship between Glucuronidase Activity and Tumour Sensitivity , 1966, Nature.

[29]  R. Warnick,et al.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.

[30]  K. Bagshawe.  Antibody‐directed enzyme prodrug therapy: A review , 1995 .

[31]  M. Tanimoto,et al.  Transduction of a Drug-Sensitive Toxic Gene into Human Leukemia Cell Lines with a Novel Retroviral Vector , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[32]  K. Blankenburg,et al.  In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. , 1996, Gynecologic oncology.

[33]  C. Springer,et al.  Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. , 1995, European journal of cancer.

[34]  F. Friedlos,et al.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT) , 1993, Cancer and Metastasis Reviews.

[35]  R. Sherwood,et al.  Antibody-enzyme conjugates for cancer therapy. , 1996, Journal of the National Cancer Institute.

[36]  C. Richards,et al.  Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Connors Ta.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995 .

[38]  N. Minton,et al.  Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. , 1994, FEMS microbiology letters.

[39]  H. Ito,et al.  Immunotoxins containing glucose oxidase and lactoperoxidase with tumoricidal properties: in vitro killing effectiveness in a mouse plasmacytoma cell model. , 1989, Cancer research.

[40]  C. Springer,et al.  Antibody directed enzyme prodrug therapy (ADEPT): clinical report. , 1991, Disease markers.

[41]  K. Bagshawe.  ADEPT and related concepts , 2007, Cell Biophysics.

[42]  R. Blaese,et al.  Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[43]  B. Teicher,et al.  Preclinical studies and clinical correlation of the effect of alkylating dose. , 1988, Cancer research.

[44]  F. Gage,et al.  Thymidine kinase-mediated killing of rat brain tumors. , 1993, Journal of neurosurgery.

[45]  C. Springer,et al.  Identification of prodrug, active drug, and metabolites in an ADEPT clinical study , 2009, Cell Biophysics.

[46]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[47]  T. Atkinson,et al.  The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2. , 1984, Gene.

[48]  S. Woo,et al.  Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. , 1995, Cancer research.

[49]  D. Kieback,et al.  Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. , 1996, Anticancer research.

[50]  R. Grossman,et al.  Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  F. Friedlos,et al.  Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. , 1994, Journal of medicinal chemistry.

[52]  J. Olsen,et al.  Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. , 1996, Cancer research.

[53]  B. Davidson,et al.  Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. , 1994, Cancer research.

[54]  A. Marrogi,et al.  In situ use of suicide genes for cancer therapy. , 1996, Seminars in oncology.

[55]  I. Maxwell,et al.  Suppression of single and double nonsense mutations introduced into the diphtheria toxin A-chain gene: a potential binary system for toxin gene therapy. , 1995, Human gene therapy.

[56]  C. Mullen,et al.  Metabolic suicide genes in gene therapy. , 1994, Pharmacology & therapeutics.

[57]  T. A. Connors,et al.  Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy. , 1996, Gene therapy.

[58]  Joseph S. Fruton,et al.  The Collected Papers of Paul Ehrlich , 1957, The Yale Journal of Biology and Medicine.

[59]  J. Watson,et al.  An examination of the relative resistances to aflatoxin B1 and susceptibilities to γ-glutamyl p-phenylene diamine mustard of γ-glutamyl transferase negative and positive cell lines , 1981 .

[60]  Wawrzynczak Ej.  Systemic immunotoxin therapy of cancer: advances and prospects. , 1991 .

[61]  W. Denny,et al.  Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. , 1997, Journal of medicinal chemistry.

[62]  R. Vile,et al.  Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. , 1994, Cancer research.

[63]  F. Friedlos,et al.  CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. , 1986, Biochemical and biophysical research communications.

[64]  J. Katzenellenbogen,et al.  A novel connector linkage applicable in prodrug design. , 1981, Journal of medicinal chemistry.

[65]  D. Blakey,et al.  Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Wells,et al.  Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. , 1992, Cancer letters.

[67]  L. M. Cobb,et al.  2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. , 1969, Biochemical pharmacology.

[68]  C. Springer,et al.  The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. , 1997, Human gene therapy.

[69]  T. A. Connors.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995, Gene therapy.

[70]  S. Sharma,et al.  Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  D. Klatzmann,et al.  Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". , 1996, Cancer gene therapy.

[72]  H. Fine,et al.  Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. , 1995, The Journal of clinical investigation.

[73]  W F Anderson,et al.  Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. , 1993, Human gene therapy.

[74]  H. Fine,et al.  Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. , 1994, Cancer research.

[75]  O. Cochet,et al.  Phage libraries for generation of clinically useful antibodies , 1994, The Lancet.

[76]  C. Monneret,et al.  Fusion protein mediated prodrug activation (FMPA) in vivo , 2007, Cell Biophysics.

[77]  F. Friedlos,et al.  Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system. , 1992, Biochemical pharmacology.

[78]  W. Denny,et al.  A NOVEL ENEDIYNE PRODRUG FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) USING E. COLI B NITROREDUCTASE , 1995 .

[79]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[80]  D. Melzack,et al.  Studies on the mechanism of action of 5‐aziridinyl‐2,4‐dinitrobenzamide (CB 1954), a selective inhibitor of the walker tumour , 1971, International journal of cancer.

[81]  Z. Ram,et al.  Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. , 1993, Journal of neurosurgery.

[82]  X. Breakefield,et al.  Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. , 1994, Human gene therapy.

[83]  M. Israel,et al.  The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[84]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy (ADEPT): a review. , 1997, Advanced drug delivery reviews.

[85]  E. Wawrzynczak.  Systemic immunotoxin therapy of cancer: advances and prospects. , 1991, British Journal of Cancer.

[86]  T. A. Connors,et al.  New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link. , 1996, Journal of medicinal chemistry.

[87]  D. Klatzmann,et al.  Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[88]  H. Wakimoto,et al.  Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. , 1996, Cancer research.

[89]  W. Denny,et al.  A novel nitro-substituted seco-CI: Application as a reductively activated adept prodrug , 1996 .

[90]  M. Grever,et al.  Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. , 1996, Journal of the National Cancer Institute.

[91]  J. Watson,et al.  An examination of the relative resistances to aflatoxin B1 and susceptibilities to gamma-glutamyl p-phenylene diamine mustard of gamma-glutamyl transferase negative and positive cell lines. , 1981, Carcinogenesis.

[92]  R. Blaese,et al.  Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. , 1994, Cancer research.

[93]  W. Denny,et al.  Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. , 1995, Biochemical pharmacology.

[94]  I. Maxwell,et al.  Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-lymphoid malignancy. , 1992, Leukemia & lymphoma.

[95]  M L Mendelsohn,et al.  The growth fraction, a new concept applied to tumors. Abstr. , 1960 .

[96]  F. Friedlos,et al.  The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. , 1992, Biochemical pharmacology.

[97]  C. Richards,et al.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[98]  R. Vile,et al.  Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. , 1993, Cancer research.

[99]  C. Richards,et al.  In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. , 1993, Cancer research.